HC Wainwright Issues Negative Outlook for Celcuity Earnings

Celcuity, Inc. (NASDAQ:CELC) – Equities research analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for Celcuity in a research note issued to investors on Wednesday, July 15th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($1.22) per share for the quarter, down from their prior forecast of ($1.17). HC Wainwright currently has a “Buy” rating and a $155.00 target price on the stock. The consensus estimate for Celcuity’s current full-year earnings is ($3.76) per share. HC Wainwright also issued estimates for Celcuity’s Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($4.12) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.23) EPS and FY2027 earnings at ($0.95) EPS.

A number of other brokerages also recently weighed in on CELC. Craig Hallum reiterated a “buy” rating and issued a $178.00 target price on shares of Celcuity in a report on Wednesday. Wells Fargo & Company decreased their price target on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Citigroup reaffirmed an “outperform” rating on shares of Celcuity in a research report on Wednesday. Weiss Ratings upgraded shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. Finally, Stifel Nicolaus set a $150.00 target price on shares of Celcuity in a research report on Monday, May 4th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $155.18.

Celcuity Trading Up 0.1%

Shares of NASDAQ CELC opened at $88.38 on Friday. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. Celcuity has a one year low of $13.47 and a one year high of $151.02. The business has a 50-day moving average price of $108.17 and a two-hundred day moving average price of $110.80. The firm has a market capitalization of $4.31 billion, a PE ratio of -22.66 and a beta of 0.16.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.10.

Hedge Funds Weigh In On Celcuity

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CELC. Avoro Capital Advisors LLC bought a new stake in shares of Celcuity in the 4th quarter valued at approximately $310,302,000. NEA Management Company LLC grew its holdings in shares of Celcuity by 64.9% during the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after purchasing an additional 1,391,300 shares during the last quarter. State Street Corp increased its position in Celcuity by 126.6% in the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after acquiring an additional 914,887 shares in the last quarter. UBS Group AG increased its holdings in shares of Celcuity by 910.1% in the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after purchasing an additional 769,891 shares in the last quarter. Finally, Deerfield Management Company L.P. acquired a new stake in shares of Celcuity in the 3rd quarter valued at $36,236,000. Institutional investors own 63.33% of the company’s stock.

Insider Activity

In other news, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the sale, the director directly owned 65,000 shares in the company, valued at $9,144,200. The trade was a 27.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. The trade was a 57.11% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.33% of the company’s stock.

More Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity won FDA approval for REVTORPYK in advanced HR+/HER2- breast cancer, a key catalyst that validates the drug and could support future revenue growth. Celcuity gains FDA approval for closely watched breast cancer drug
• Positive Sentiment: Several recent coverage items highlight optimism that the approval could position Celcuity as a more attractive oncology asset, even raising speculation it could draw interest from larger pharmaceutical companies. With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
• Neutral Sentiment: HC Wainwright kept a Buy rating and $155 price target, but trimmed earnings estimates for FY2026 and multiple 2027 periods, reflecting a more cautious near-term profit outlook despite the long-term story remaining intact.
• Negative Sentiment: Investor concern is building around commercialization timing and rollout execution, which has led some reports to say the FDA approval was not enough to offset questions about launch speed and market uptake. Celcuity Shares Down, FDA Approval Outweighed by Timeline Questions for Breast-Cancer Treatment
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Celcuity investors, adding a legal overhang that can pressure sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. – CELC

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.